EVALUATION OF EFFICACY OF SAMEUP IN SUBJECTS WITH DEPRESSION SYMPTOMS: A RANDOMIZED STUDY
- Conditions
- Depressive Symptoms
- Interventions
- Other: PlaceboCombination Product: SAMEUp
- Registration Number
- NCT03932474
- Lead Sponsor
- Nutrilinea srl
- Brief Summary
This study is planned to assess the efficacy of SAMEUp versus placebo after six weeks of treatment in subjects characterized by depression symptoms according to ICD-10 (International Classification of Diseases - 10th revision) diagnostic criteria and confirmed by mean of Zung's Self-Rating Depression Scale.
- Detailed Description
Depression is a common condition of low mood and aversion to activity that can affect a person's thoughts, behaviour, tendencies, feelings, and sense of well-being.
Several literature findings suggest that an oral combination of the two food supplements SAMe (S-adenosyl-L-methionine) and probiotic Lactobacillus plantarum might be favourable in relieving some of symptoms of depression, particularly in the mild to moderate forms of this condition. This double blind placebo controlled clinical study aims to evaluate this hypothesis. In particular, the primary objective is to assess, versus placebo, the efficacy of SAMEUp in improving the overall symptomology of depression after 6 weeks of treatment. Subjects with mild to moderate depression were identified according to ICD-10 diagnostic criteria and confirmed by mean of Zung's Self-Rating Depression Scale.
SAMEUp, the investigational food supplement, is an oral formulation (tablet) containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU, already notified to the Ministry of Health as food supplement.
Placebo is an oral formulation of inert tablet. Placebo and SAMEUp are indistinguishable.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 90
- Written informed consent, personally signed and dated by the subject.
- Males and females, aging 18-60 years old (limits included).
- Diagnosis of mild to moderate recurrent depressive disorder according to the ICD-10 / F33 criteria (World Health Organization, 2004).
- Subject who, having completed the Z-SDS depression questionnaire, has a raw score between 41 and 55 (including limits).
- Subject able to comprehend the full nature and purpose of the study, available to cooperate with the Investigator and to comply with the requirements of the entire study.
- Pregnant or breast-feeding woman.
- Subject with one or more psychiatric disturbances, such as: alcoholism, substance abuse or dependency disorder, bipolar disorder, schizophrenia, or other personality disorder.
- Subject with known or potential hypersensitivity to any ingredient in the study product.
- Subject in treatment with psycholeptic drug, such as: antipsychotics, anxiolytics, hypnotics and sedatives.
- Subject who has taken during the 2 weeks prior to inclusion, who is currently taking or plans to take other orally administered food supplements except the study product. Only multivitamins, salts and trace elements are accepted
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Placebo is an oral formulation of inert tablet. Placebo and SAMEUp are identical in shape, size, colour and taste. SAMEUp SAMEUp SAMEUp, the Investigational Food Supplement (IFS), is an oral formulation (tablet) containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
- Primary Outcome Measures
Name Time Method Improvement in the overall depression symptomatology assessed by the Zung's Self-Rating Depression Scale 6 weeks Absolute change from baseline to six treatment-week of the total score of the Zung's Self-Rating Depression Scale
- Secondary Outcome Measures
Name Time Method Improvement in the overall depression symptomatology assessed by the Zung's Self-Rating Depression Scale 2 weeks Absolute change from baseline to two treatment-week of the total score of the Zung's Self-Rating Depression Scale
Incidence of adverse events described as per frequency and relationship with the study product 6 weeks Adverse events occurrence during the study
Improvement in the core depression symptomatology assessed by Zung's Self-Rating Depression Scale 6 weeks Absolute change from baseline to six treatment-week of the core depressive factor of the Zung's Self-Rating Depression Scale.
Improvement in the patient's cognition assessed by Zung's Self-Rating Depression Scale 6 weeks Absolute change from baseline to six treatment-week of the cognitive factor of the Zung's Self-Rating Depression Scale.
Improvement in the somatic condition assessed by Zung's Self-Rating Depression Scale 6 weeks Absolute change from baseline to six treatment-week of the somatic factor of the Zung's Self-Rating Depression Scale.
Improvement in IBS (Irritable Bowel Syndrome) symptoms evaluated through the IBS questionnaire 2 weeks Absolute change from baseline to two treatment-week of the total score of the IBS questionnaire.
Improvement in the overall symptomatology of depression assessed by Zung's Self-Rating Depression Scale 6 weeks Absolute change from baseline to six treatment-week of the total score of the Zung's Self-Rating Anxiety Scale.
Improvement in the anxiety condition assessed by Zung's Self-Rating Depression Scale 6 weeks Absolute change from baseline to six treatment-week of the anxiety factor of the Zung's Self-Rating Depression Scale.
Improvement in the insomnia condition evaluated through the Insomnia Severity Index 6 weeks Absolute change from baseline to six treatment-week of the total score of the Insomnia Severity Index.
Improvement in IBS symptoms evaluated through the IBS questionnaire 6 weeks Absolute change from baseline to six treatment-week of the total score of the IBS questionnaire.
Improvement in the overall health status as measured by the EQ-5D-3L questionnaire 6 weeks Absolute change from baseline to six treatment-week of the EQ-5D-3L questionnaire.
Evaluation of the patient's satisfaction grade 6 weeks Subject's satisfaction grade at the end of the treatment.
Trial Locations
- Locations (1)
Hippocrates Research
🇮🇹Genoa, Italy